revasc
play

REVASC ClinicalTrials.gov, Identifier: NCT01924962 Recovery of Left - PowerPoint PPT Presentation

Feb 13, 2024 •277 likes •494 views

REVASC ClinicalTrials.gov, Identifier: NCT01924962 Recovery of Left Ventricular Function in Coronary Chronic Total Occlusion K. Mashayekhi, T. Nhrenberg, A.Toma, M.Gick, M. Ferenc, W. Hochholzer, T. Comberg, J. Rothe, C.Valina, N.

  1. REVASC ClinicalTrials.gov, Identifier: NCT01924962 Recovery of Left Ventricular Function in Coronary Chronic Total Occlusion K. Mashayekhi, T. Nührenberg, A.Toma, M.Gick, M. Ferenc, W. Hochholzer, T. Comberg, J. Rothe, C.Valina, N. Löffelhardt, M. Ayoub, M.Zhao, J.Bremicker, N. Jander, J.Minners, P. Ruile, M. Behnes, I. Akin, T. Schäufele, F. -J. Neumann, H.-J. Büttner. University Heart Center Freiburg · Bad Krozingen Bad Krozingen / Germany

  2. Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company • • Grant/Research Support REVASC was sponsored by Cordis • Consulting Fees/Honoraria • Ashai Intecc, Vascular Solutions, Cordis, Abboth, Biotronik, Terumo, AstraZeneca, Daiichi Sankyo

  3. Randomized Trials Trial N Study Type Population Primary Endpoints: 304 CTO PCI vs. no STEMI with 4-month: LVEF, LVEDV per MRI EXPLORE CTO PCI CTO comparable in both groups 834 CTO PCI + OMT Stable Angina 3-year death, MI, stroke, or repeat DECISION- vs. OMT or ACS revascularization comparable in CTO both groups 396 CTO PCI + OMT Stable angina PCI group experienced lower angina EURO-CTO vs. OMT frequency per SAQ

  4. REVASC Trial Recovery of Left Ventricular Function After Stent Implantation in Chronic Total Occlusion of Coronary Arteries : Objective Background • Whether percutaneous coronary • We evaluated whether PCI of intervention (PCI) in chronic CTO (CTO-PCI) improves left occluded coronary arteries ventricular function in addition (CTO) may improve outcomes to PCI of relevant coexisting compared to optimal medical non-CTO vessels (no-CTO-PCI). therapy (OMT) is still controversial.

  5. Primary Endpoint: Segmental wall thickening (SWT) measured by cMRI after 6 months Baseline 6 months Modified from Kirschbaum SW et al, JACC Cardiovasc Imaging. 2010 Jun;3(6):614-22

  6. Study endpoints • Primary endpoint:  Change in segmental wall thickening (SWT) in the CTO territory according to the 17-segment model between baseline and follow-up at 6 months • Secondary endpoints:  Changes in LV end-diastolic and end-systolic volume indices and left ventricular ejection fraction (LVEF) • Clinical outcomes:  MACE at 12 months was defined as all-cause death, myocardial infarction and any clinically driven repeat revascularization.

  7. Patient selection Major inclusion criteria Exclusion criteria • CTO with an estimated • Left ventricular ejection fraction reference vessel diameter of 2.5- < 25% 4.0mm. • Acute coronary syndrome < 72 hours preceding the index procedure • Clinical symptoms or positive • Contraindications to cMRI functional study for ischemia

  8. Estimation of sample size • Hypothesis: 15%-recovery of SWT with CTO-PCI versus a 2%-recovery with No-CTO- PCI at a common standard deviation of 30%. • Goal: 80% power, level of significance 5% • Sample size: 85 patients per study arm • Recruitment: 200 patients (to account for losses to follow-up)

  9. Study flow of REVASC

  10. Baseline demographic and angiographic characteristics no-CTO-PCI CTO-PCI p Value (n = 104) (n = 101) Age (years) 68 [61 - 74] 65 [57 - 72] 0.02 Male gender 90 (86.5) 91 (90.1) 0.43 Diabetes 31 (29.8) 32 (31.6) 0.77 LVEF (%) 59.6 [45.8 - 64.3] 54.7 [42.9 - 65.1] 0.48 Previous PCI 33 (31.7) 28 (27.7) 0.53 Previous myocardial 38 (36.5) 39 (38.6) 0.76 infarction Previous bypass operation 14 (13.5) 12 (11.9) 0.73

  11. Angiographic characteristics no-CTO-PCI CTO-PCI p Value (n = 104) (n = 101) Coronary artery disease 0.55 1-vessel disease 10 (9.6) 14 (13.9) 2,3-vessel disease 94 (90.4) 87 (86.1) SYNTAX-Score 16 [11 - 21] 14 [9 - 22] 0.33 Residual SYNTAX-Score 11 [8 - 16] 2 [0 - 7] <0.01 J-CTO Score 2 [1 – 3] 2 [1 - 2] 0.43 PROGRESS Score 0 [0 – 1] 1 [0 – 1] <0.01

  12. Procedural CTO data CTO-PCI (n = 101) CTO recanalization technique antegrade only 61 (60.4) retrograde 40 (39.6) Technical success on first attempt 87 (86.1) Technical success including 2 nd attempts 100 (99.0) 96 [65 – 149] Procedure time (minutes) 37 [20 – 76] Fluoroscopy time (minutes) 10322 [5725 – 17539] Radiation dose (µGy*cm²) 280 [200 – 400] Contrast Volume (ml)

  13. Primary endpoint: p = 0.57 p = 0.57 Change in Segmental Wall Thickening (%) 40 200 Segmental Wall Thickening (%) 150 20 100 0 50 0 -20 baseline baseline 6M FU 6M FU All CTO segments -50 OMT  OMT + -40 no-CTO PCI CTO PCI OMT  no-CTO PCI OMT + CTO PCI All CTO segments

  14. Primary endpoint: p = 0.51 Change in Segmental Wall Thickening (%) p = 0.51 Segmental Wall Thickening (%) 200 40 150 20 100 0 50 0 -20 baseline 6M FU baseline 6M FU Dysfunctional CTO -50 segments OMT  OMT + no-CTO PCI CTO PCI -40 OMT  no-CTO PCI OMT + CTO PCI Dysfunctional CTO segments

  15. Primary endpoint: p = 0.12 p = 0.12 Change in Segmental Wall Thickening (%) 40 200 Segmental Wall Thickening (%) 150 20 100 0 50 0 -20 baseline 6M FU baseline 6M FU Patients with -50 OMT  SYNTAX score < 13 OMT + no-CTO PCI CTO PCI -40 OMT  no-CTO PCI Patients with SYNTAX Score < 13 OMT + CTO PCI

  16. Secondary endpoint: LVEF LVEDV index 300 p = 0.79 p = 0.54 100 LVEDV index (ml/m²) 80 200 LVEF (%) 60 40 100 20 0 0 baseline 6M FU baseline 6M FU baseline 6M FU baseline 6M FU OMT  OMT  OMT + OMT + non-CTO PCI CTO PCI CTO PCI non-CTO PCI

  17. Major adverse cardiac events at 12 months (death, infarction, any revascularization)

  18. Major adverse cardiac events at 12 months no-CTO-PCI CTO-PCI (n = 104) (n = 101) MACE 17 (18.2) 6 (5.9) Death of any cause at 12 months 2 (2.0) 1 (1.0) Acute myocardial infarction 1 (1.0) 0 (0.0) Clinically driven repeat revascularization at 16 (15.4) 5 (5.0) 12 months: CTO vessel 14 (13.5) 3 (3.0)

  19. Conclusion • In the entire cohort, CTO-PCI did not improve regional or global left ventricular function over no-CTO PCI. • In the subset of patients without major non-CTO lesions, CTO-PCI was associated with a trend towards larger improvement in segmental wall thickening than no-CTO-PCI. • In the entire cohort, CTO-PCI resulted in clinical benefit over no CTO-PCI as evidenced by reduced MACE rates at 12 months.

  20. Primary endpoint: Change of SWT in % p = 0.51 p = 0.57 p = 0.12 Change in Segmental Wall Thickening (%) 40 20 OMT  non-CTO PCI OMT + CTO PCI 0 -20 patients with dysfunctional all SYNTAX score < 13 -40 CTO areas

Recommend

More recommend